메뉴 건너뛰기




Volumn 18, Issue 1, 2017, Pages

Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; EPO PROTEIN, HUMAN;

EID: 85037035032     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-017-0688-1     Document Type: Article
Times cited : (192)

References (182)
  • 1
    • 43049113533 scopus 로고    scopus 로고
    • GRADE: An emerging consensus on rating quality of evidence and strength of recommendations
    • 18436948 2335261
    • Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
    • (2008) BMJ , vol.336 , pp. 924-926
    • Guyatt, G.H.1    Oxman, A.D.2    Vist, G.E.3
  • 2
    • 33845343267 scopus 로고    scopus 로고
    • Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: Improving global outcomes (KDIGO)
    • 1:STN:280:DC%2BD28npslyktQ%3D%3D 17003817
    • Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;70:2058-65.
    • (2006) Kidney Int , vol.70 , pp. 2058-2065
    • Uhlig, K.1    MacLeod, A.2    Craig, J.3
  • 3
    • 85037037728 scopus 로고    scopus 로고
    • National Collaborating Centre for Chronic Conditions, Royal College of Physicians National Institute for Clinical Excellence Accessed 15 June 2017
    • National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on anaemia management in chronic kidney disease. 2015. National Institute for Clinical Excellence. Available on http://www.nice.org.uk/guidance/NG8/evidence. Accessed 15 June 2017.
    • (2015) Guideline on Anaemia Management in Chronic Kidney Disease
  • 4
    • 85037058588 scopus 로고    scopus 로고
    • National Collaborating Centre for Chronic Conditions, Royal College of Physicians National Institute for Clinical Excellence Accessed 15 June 2017
    • National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on chronic kidney disease in adults: assessment and management 2014. National Institute for Clinical Excellence. Available on http://www.nice.org.uk/guidance/cg182. Accessed 15 June 2017.
    • Guideline on Chronic Kidney Disease in Adults: Assessment and Management 2014
  • 5
    • 4344581912 scopus 로고    scopus 로고
    • Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure
    • Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. NephrolDialTransplant. 2004;19(Suppl 2):ii1-47.
    • (2004) NephrolDialTransplant , vol.19 , pp. ii1-i47
    • Locatelli, F.1    Aljama, P.2    Barany, P.3
  • 6
    • 84879836673 scopus 로고    scopus 로고
    • Kidney disease: Improving global outcomes guidelines on anaemia management in chronic kidney disease: A European renal best practice position statement
    • Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346-59.
    • (2013) Nephrol Dial Transplant. , vol.28 , Issue.6 , pp. 1346-1359
    • Locatelli, F.1    Bárány, P.2
  • 7
    • 33646339958 scopus 로고    scopus 로고
    • National Kidney Foundation clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease in adults
    • KDOQI
    • KDOQI. National Kidney Foundation clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 Suppl 3):S16-85.
    • (2006) Am J Kidney Dis , vol.47 , Issue.5 , pp. S16-S85
  • 8
    • 84884333035 scopus 로고    scopus 로고
    • Clinical practice guideline for Anaemia in chronic kidney disease
    • KDIGO
    • KDIGO. Clinical practice guideline for Anaemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279-335.
    • (2012) Kidney Int Suppl , vol.2 , pp. 279-335
  • 9
    • 9144239992 scopus 로고    scopus 로고
    • Effects of early and late intervention with epoetin α on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial
    • 1:CAS:528:DC%2BD2cXhs1aitQ%3D%3D 14694167
    • Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin α on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148-56.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 148-156
    • Roger, S.D.1    McMahon, L.P.2    Clarkson, A.3
  • 10
    • 27144539133 scopus 로고    scopus 로고
    • Canadian randomized trial of haemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD
    • 1:CAS:528:DC%2BD2MXht1Olu77O 16253719
    • Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of haemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46:799-811.
    • (2005) Am J Kidney Dis , vol.46 , pp. 799-811
    • Levin, A.1    Djurdjev, O.2    Thompson, C.3
  • 13
    • 0023583847 scopus 로고
    • Haemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet
    • 1:STN:280:DyaL1c%2FitFansA%3D%3D 3661681
    • Beall CM, Goldstein MC. Haemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet. Am J Phys Anthropol. 1987;73:433-8.
    • (1987) Am J Phys Anthropol , vol.73 , pp. 433-438
    • Beall, C.M.1    Goldstein, M.C.2
  • 14
    • 1842484334 scopus 로고    scopus 로고
    • Complete blood count reference interval diagrams derived from NHANES III: Stratification by age, sex, and race
    • 15070217
    • Cheng CK, Chan J, Cembrowski GS, van Assendelft OW. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Lab Hematol. 2004;10:42-53.
    • (2004) Lab Hematol , vol.10 , pp. 42-53
    • Cheng, C.K.1    Chan, J.2    Cembrowski, G.S.3    Van Assendelft, O.W.4
  • 15
    • 19744368621 scopus 로고    scopus 로고
    • Identifying patients with chronic kidney disease from general practice computer records
    • 15814579
    • de Lusignan S, Chan T, Stevens P, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22:234-41.
    • (2005) Fam Pract , vol.22 , pp. 234-241
    • De Lusignan, S.1    Chan, T.2    Stevens, P.3
  • 16
    • 4944261763 scopus 로고    scopus 로고
    • Prevalence of anaemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anaemia
    • 1:CAS:528:DC%2BD2cXovVegsbc%3D 15238427
    • Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anaemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anaemia. Blood. 2004;104:2263-8.
    • (2004) Blood , vol.104 , pp. 2263-2268
    • Guralnik, J.M.1    Eisenstaedt, R.S.2    Ferrucci, L.3
  • 17
    • 13144255700 scopus 로고    scopus 로고
    • Diabetes mellitus increases the severity of anaemia in non-dialyzed patients with renal failure
    • 1:STN:280:DyaK1c3ltFartg%3D%3D 9589379
    • Ishimura E, Nishizawa Y, Okuno S, et al. Diabetes mellitus increases the severity of anaemia in non-dialyzed patients with renal failure. J Nephrol. 1998;11:83-6.
    • (1998) J Nephrol , vol.11 , pp. 83-86
    • Ishimura, E.1    Nishizawa, Y.2    Okuno, S.3
  • 18
    • 0035094695 scopus 로고    scopus 로고
    • Anaemia with erythropoietin deficiency occurs early in diabetic nephropathy
    • 1:STN:280:DC%2BD3M7pslCmug%3D%3D 11289474
    • Bosman DR, Winkler AS, Marsden JT, et al. Anaemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24:495-9.
    • (2001) Diabetes Care , vol.24 , pp. 495-499
    • Bosman, D.R.1    Winkler, A.S.2    Marsden, J.T.3
  • 19
    • 0043244908 scopus 로고    scopus 로고
    • Unrecognized anaemia in patients with diabetes: A cross-sectional survey
    • 12663591
    • Thomas MC, MacIsaac RJ, Tsalamandris C, et al. Unrecognized anaemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003;26:1164-9.
    • (2003) Diabetes Care , vol.26 , pp. 1164-1169
    • Thomas, M.C.1    MacIsaac, R.J.2    Tsalamandris, C.3
  • 20
    • 3242725819 scopus 로고    scopus 로고
    • The burden of anaemia in type 2 diabetes and the role of nephropathy: A cross-sectional audit
    • 15102962
    • Thomas MC, MacIsaac RJ, Tsalamandris C, et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant. 2004;19:1792-7.
    • (2004) Nephrol Dial Transplant , vol.19 , pp. 1792-1797
    • Thomas, M.C.1    MacIsaac, R.J.2    Tsalamandris, C.3
  • 21
    • 16244379523 scopus 로고    scopus 로고
    • Higher prevalence of anaemia with diabetes mellitus in moderate kidney insufficiency: The kidney early evaluation program
    • 15780101
    • El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anaemia with diabetes mellitus in moderate kidney insufficiency: the kidney early evaluation program. Kidney Int. 2005;67:1483-8.
    • (2005) Kidney Int , vol.67 , pp. 1483-1488
    • El-Achkar, T.M.1    Ohmit, S.E.2    McCullough, P.A.3
  • 22
    • 0029371783 scopus 로고
    • The rate and control of baseline red cell production in haematologically stable patients with uraemia
    • 1:STN:280:DyaK2MzpsFemtw%3D%3D 7665976
    • Erslev AJ, Besarab A. The rate and control of baseline red cell production in haematologically stable patients with uraemia. J Lab Clin Med. 1995;126(3):283-6.
    • (1995) J Lab Clin Med , vol.126 , Issue.3 , pp. 283-286
    • Erslev, A.J.1    Besarab, A.2
  • 23
    • 0022880011 scopus 로고
    • Radioimmunoassay of erythropoietin in chronic uraemia or nephric patients
    • 1:STN:280:DyaL2s7itVSltw%3D%3D 3810037
    • Naets JP, Garcia JF, Tousaaint C, et al. Radioimmunoassay of erythropoietin in chronic uraemia or nephric patients. Scand J Haematol. 1986;37:390-4.
    • (1986) Scand J Haematol , vol.37 , pp. 390-394
    • Naets, J.P.1    Garcia, J.F.2    Tousaaint, C.3
  • 24
    • 0028465477 scopus 로고
    • Erythropoietin response to blood loss in haemodialysis patients in blunted but preserved
    • 1:STN:280:DyaK287ksFCrsA%3D%3D 8555638
    • Ross RP, McCrea JB, Besarab A. Erythropoietin response to blood loss in haemodialysis patients in blunted but preserved. ASAIO J. 1994;40:M880-5.
    • (1994) ASAIO J , vol.40 , pp. M880-M885
    • Ross, R.P.1    McCrea, J.B.2    Besarab, A.3
  • 25
    • 0036194646 scopus 로고    scopus 로고
    • Pre dialysis versus post dialysis haematocrit evaluation during erythropoietin therapy
    • 1:CAS:528:DC%2BD38XjtFOgu74%3D 11920353
    • Movilli E, Pertica N, Camerini C, et al. Pre dialysis versus post dialysis haematocrit evaluation during erythropoietin therapy. Am J Kidney Dis. 2002;39:850-3.
    • (2002) Am J Kidney Dis , vol.39 , pp. 850-853
    • Movilli, E.1    Pertica, N.2    Camerini, C.3
  • 26
    • 0036724378 scopus 로고    scopus 로고
    • Influence of the cyclic variation of hydration status on haemoglobin levels in haemodialysis patients
    • 1:CAS:528:DC%2BD38Xntl2ltbc%3D 12200807
    • Bellizzi V, Minutolo R, Terracciano V, et al. Influence of the cyclic variation of hydration status on haemoglobin levels in haemodialysis patients. Am J Kidney Dis. 2002;40:549-55.
    • (2002) Am J Kidney Dis , vol.40 , pp. 549-555
    • Bellizzi, V.1    Minutolo, R.2    Terracciano, V.3
  • 27
    • 0028883717 scopus 로고
    • The efficacy of iron dextran for the treatment of iron deficiency in haemodialysis patients
    • 1:CAS:528:DyaK2MXpslSqtr4%3D 8575123
    • Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in haemodialysis patients. Clin Nephrol. 1995;44:238-40.
    • (1995) Clin Nephrol , vol.44 , pp. 238-240
    • Fishbane, S.1    Lynn, R.I.2
  • 29
    • 0029151510 scopus 로고
    • Diagnosis of iron deficiency anaemia in renal failure patients during the post-erythropoietin era
    • 1:STN:280:DyaK2MzntlCkug%3D%3D 7645533
    • Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Luft FC, et al. Diagnosis of iron deficiency anaemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995;26:292-9.
    • (1995) Am J Kidney Dis , vol.26 , pp. 292-299
    • Kalantar-Zadeh, K.1    Hoffken, B.2    Wunsch, H.3    Fink, H.4    Luft, F.C.5
  • 30
    • 85037034455 scopus 로고    scopus 로고
    • KDOQI guidelines on anaemia management Accessed 15 June 2017
    • KDOQI guidelines on anaemia management: http://www2.kidney.org/professionals/KDOQI/guidelines-anemia/guide1.htm. Accessed 15 June 2017.
  • 31
    • 17444443582 scopus 로고    scopus 로고
    • Iron deficiency anaemia in the elderly: Prevalence and endoscopic evaluation of the gastrointestinal tract in outpatients
    • 1:CAS:528:DC%2BD3sXntlShu7Y%3D 12975553
    • Coban E, Timuragaoglu A, Meric M. Iron deficiency anaemia in the elderly: prevalence and endoscopic evaluation of the gastrointestinal tract in outpatients. Acta Haematol. 2003;110:25-8.
    • (2003) Acta Haematol , vol.110 , pp. 25-28
    • Coban, E.1    Timuragaoglu, A.2    Meric, M.3
  • 32
    • 0036702366 scopus 로고    scopus 로고
    • Iron deficiency and gastrointestinal malignancy: A population-based cohort study
    • 1:CAS:528:DC%2BD38XnsVait7w%3D 12361812
    • Ioannou GN, Rockey DC, Bryson CL, et al. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med. 2002;113:276-80.
    • (2002) Am J Med , vol.113 , pp. 276-280
    • Ioannou, G.N.1    Rockey, D.C.2    Bryson, C.L.3
  • 33
    • 0036701644 scopus 로고    scopus 로고
    • Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anaemia
    • 12361813
    • Ioannou GN, Spector J, Scott K, et al. Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anaemia. Am J Med. 2002;113:281-7.
    • (2002) Am J Med , vol.113 , pp. 281-287
    • Ioannou, G.N.1    Spector, J.2    Scott, K.3
  • 34
    • 0034088831 scopus 로고    scopus 로고
    • Optimization of epoetin therapy with intravenous iron therapy in haemodialysis patients
    • 1:CAS:528:DC%2BD3cXhslWmsbw%3D 10703677
    • Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in haemodialysis patients. J Am Soc Nephrol. 2000;11:530-8.
    • (2000) J Am Soc Nephrol , vol.11 , pp. 530-538
    • Besarab, A.1    Amin, N.2    Ahsan, M.3
  • 35
    • 0035428020 scopus 로고    scopus 로고
    • Maintaining higher TSATs and other iron indices is beneficial in management of anaemic haemodialysis patients
    • 1:STN:280:DC%2BD38zpsVCmsQ%3D%3D 12143465
    • Besarab A, Dalton CL. Maintaining higher TSATs and other iron indices is beneficial in management of anaemic haemodialysis patients. Nephrol Nurs J. 2001;28:429-34.
    • (2001) Nephrol Nurs J , vol.28 , pp. 429-434
    • Besarab, A.1    Dalton, C.L.2
  • 37
    • 0141508878 scopus 로고    scopus 로고
    • Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance haemodialysis patients
    • 14520627
    • Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance haemodialysis patients. Am J Kidney Dis. 2003;42:761-73.
    • (2003) Am J Kidney Dis , vol.42 , pp. 761-773
    • Kalantar-Zadeh, K.1    McAllister, C.J.2    Lehn, R.S.3
  • 38
    • 0035349564 scopus 로고    scopus 로고
    • Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult haemodialysis patients: Results from the 1998 end-stage renal disease Core indicators project
    • 1:STN:280:DC%2BD3MrlsFCisQ%3D%3D 11325701
    • McClellan WM, Frankenfield DL, Wish JB, et al. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult haemodialysis patients: results from the 1998 end-stage renal disease Core indicators project. Am J Kidney Dis. 2001;37:E36.
    • (2001) Am J Kidney Dis , vol.37 , pp. E36
    • McClellan, W.M.1    Frankenfield, D.L.2    Wish, J.B.3
  • 39
    • 0034974917 scopus 로고    scopus 로고
    • Optimizing erythropoietin therapy in haemodialysis patients
    • 1:CAS:528:DC%2BD3MXlsVOls70%3D 11431190
    • Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in haemodialysis patients. Am J Kidney Dis. 2001;38:109-17.
    • (2001) Am J Kidney Dis , vol.38 , pp. 109-117
    • Richardson, D.1    Bartlett, C.2    Will, E.J.3
  • 40
    • 85037059696 scopus 로고    scopus 로고
    • UK Renal Registry Accessed 15 June 2017 UK Renal Registry Report: The Seventeenth Annual Report
    • UK Renal Registry. UK Renal Registry Report: The Seventeenth Annual Report. 2014. https://www.renalreg.org/wp-content/uploads/2014/12/07-Chap-07.pdf. Accessed 15 June 2017.
  • 41
    • 0035176486 scopus 로고    scopus 로고
    • A randomized trial of iron deficiency testing strategies in haemodialysis patients
    • 1:CAS:528:DC%2BD3MXpt1Kjsbg%3D 11737617
    • Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in haemodialysis patients. Kidney Int. 2001;60(6):2406-11.
    • (2001) Kidney Int , vol.60 , Issue.6 , pp. 2406-2411
    • Fishbane, S.1    Shapiro, W.2    Dutka, P.3
  • 42
    • 0030818087 scopus 로고    scopus 로고
    • Reticulocyte haemoglobin content in the evaluation of iron status of haemodialysis patients
    • 1:STN:280:DyaK2szlsFWksw%3D%3D 9211366
    • Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte haemoglobin content in the evaluation of iron status of haemodialysis patients. Kidney Int. 1997;52(1):217-22.
    • (1997) Kidney Int , vol.52 , Issue.1 , pp. 217-222
    • Fishbane, S.1    Galgano, C.2    Langley, R.C.3
  • 43
    • 0037340047 scopus 로고    scopus 로고
    • Transferrin saturation versus reticulocyte haemoglobin content for iron deficiency in Japanese haemodialysis patients
    • 1:CAS:528:DC%2BD3sXivV2jtrg%3D 12631092
    • Kaneko Y, Miyazaki S, Hirasawa Y, et al. Transferrin saturation versus reticulocyte haemoglobin content for iron deficiency in Japanese haemodialysis patients. Kidney Int. 2003;63:1086-109.
    • (2003) Kidney Int , vol.63 , pp. 1086-1109
    • Kaneko, Y.1    Miyazaki, S.2    Hirasawa, Y.3
  • 44
    • 0031956443 scopus 로고    scopus 로고
    • Reticulocyte indices in patients with end stage renal disease on haemodialysis
    • 1:STN:280:DyaK1c3ltFarsQ%3D%3D 9589378
    • Bhandari S, Turney JH, Brownjohn AM, et al. Reticulocyte indices in patients with end stage renal disease on haemodialysis. J Nephrol. 1998;11(2):78-82.
    • (1998) J Nephrol , vol.11 , Issue.2 , pp. 78-82
    • Bhandari, S.1    Turney, J.H.2    Brownjohn, A.M.3
  • 45
    • 0034945056 scopus 로고    scopus 로고
    • The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin
    • 1:CAS:528:DC%2BD3MXlvVGqtLs%3D 11427634
    • Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16(7):1416-23.
    • (2001) Nephrol Dial Transplant , vol.16 , Issue.7 , pp. 1416-1423
    • Tessitore, N.1    Solero, G.P.2    Lippi, G.3
  • 46
    • 33646800565 scopus 로고    scopus 로고
    • Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in haemodialysis patients
    • 1:CAS:528:DC%2BD28XmtlWls7o%3D 16731299
    • Chen YC, Hung SC, Tarng DC. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in haemodialysis patients. Am J Kidney Dis. 2006;47(6):1036-44.
    • (2006) Am J Kidney Dis , vol.47 , Issue.6 , pp. 1036-1044
    • Chen, Y.C.1    Hung, S.C.2    Tarng, D.C.3
  • 47
    • 85037031550 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines and clinical practice recommendations for Anaemia in chronic kidney disease. Section III. Clinical practice recommendations for anaemia in chronic kidney disease in children
    • National Kidney Foundation
    • National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for Anaemia in chronic kidney disease. Section III. Clinical practice recommendations for anaemia in chronic kidney disease in children. Am J Kidney Dis. 2006;47:S86-108.
    • (2006) Am J Kidney Dis , vol.47 , pp. S86-108
  • 48
    • 32844465284 scopus 로고    scopus 로고
    • A randomized, controlled trial comparing IV iron sucrose to oral iron in anaemic patients with non-dialysis dependent CKD
    • 16316362
    • Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anaemic patients with non-dialysis dependent CKD. Kidney Int. 2005;68:2846-56.
    • (2005) Kidney Int , vol.68 , pp. 2846-2856
    • Van Wyck, D.B.1    Roppolo, M.2    Martinez, C.O.3
  • 49
    • 0036022105 scopus 로고    scopus 로고
    • Total dose infusion iron dextran therapy in pre-dialysis chronic renal failure patients
    • 1:CAS:528:DC%2BD38XmsFagu7w%3D 12166697
    • Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in pre-dialysis chronic renal failure patients. Ren Fail. 2002;24:307-13.
    • (2002) Ren Fail , vol.24 , pp. 307-313
    • Anuradha, S.1    Singh, N.P.2    Agarwal, S.K.3
  • 50
    • 0030019635 scopus 로고    scopus 로고
    • Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis
    • 1:CAS:528:DyaK28Xhs1Shsbw%3D 8659499
    • Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234-8.
    • (1996) Am J Kidney Dis , vol.27 , pp. 234-238
    • Silverberg, D.S.1    Iaina, A.2    Peer, G.3
  • 51
    • 0035003179 scopus 로고    scopus 로고
    • A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin
    • 1:CAS:528:DC%2BD3MXktVOgsbk%3D 11328902
    • Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967-74.
    • (2001) Nephrol Dial Transplant , vol.16 , pp. 967-974
    • Stoves, J.1    Inglis, H.2    Newstead, C.G.3
  • 52
    • 20944449485 scopus 로고    scopus 로고
    • Comparison of intravenous iron sucrose to oral iron in the treatment of anaemic patients with chronic kidney disease not on dialysis
    • 1:CAS:528:DC%2BD2MXltlWrt7c%3D 15824508
    • Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anaemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55-62.
    • (2005) Nephron Clin Pract , vol.100 , pp. c55-c62
    • Charytan, C.1    Qunibi, W.2    Bailie, G.R.3
  • 53
    • 0033647567 scopus 로고    scopus 로고
    • Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: A prospective, cross-over trial
    • 1:CAS:528:DC%2BD3cXotlyltrk%3D 11045266
    • Ahsan N. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Adv Perit Dial. 2000;16:80-4.
    • (2000) Adv Perit Dial , vol.16 , pp. 80-84
    • Ahsan, N.1
  • 54
    • 84942990469 scopus 로고    scopus 로고
    • A randomized trial of intravenous and oral iron in chronic kidney disease
    • 1:CAS:528:DC%2BC2MXhtFKktb7L 26083656 4589436
    • Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88(4):905-14.
    • (2015) Kidney Int , vol.88 , Issue.4 , pp. 905-914
    • Agarwal, R.1    Kusek, J.W.2    Pappas, M.K.3
  • 55
    • 84916928192 scopus 로고    scopus 로고
    • For the FIND-CKD study investigators. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
    • 1:CAS:528:DC%2BC2sXns1ejurc%3D 24891437 4209879
    • Macdougall IC, Bock AH, Carrera F, et al. For the FIND-CKD study investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075-84.
    • (2014) Nephrol Dial Transplant , vol.29 , pp. 2075-2084
    • Macdougall, I.C.1    Bock, A.H.2    Carrera, F.3
  • 56
    • 84965179566 scopus 로고    scopus 로고
    • A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
    • 26250435
    • Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31:646-55.
    • (2016) Nephrol Dial Transplant , vol.31 , pp. 646-655
    • Kalra, P.A.1    Bhandari, S.2    Saxena, S.3
  • 57
    • 0032984416 scopus 로고    scopus 로고
    • A study of parenteral iron regimens in haemodialysis patients
    • 1:CAS:528:DyaK1MXksFegu70%3D 10401011
    • Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in haemodialysis patients. Am J Kidney Dis. 1999;34:21-8.
    • (1999) Am J Kidney Dis , vol.34 , pp. 21-28
    • Besarab, A.1    Kaiser, J.W.2    Frinak, S.3
  • 58
    • 0032873161 scopus 로고    scopus 로고
    • Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit
    • 1:CAS:528:DyaK1MXntVCmtb8%3D 10516375
    • Macdougall IC, Chandler G, Elston O, et al. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. Am J Kidney Dis. 1999;34:S40-6.
    • (1999) Am J Kidney Dis , vol.34 , pp. S40-S46
    • Macdougall, I.C.1    Chandler, G.2    Elston, O.3
  • 59
    • 0029055192 scopus 로고
    • Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation
    • 1:STN:280:DyaK2MzjsFKmsw%3D%3D 7611266
    • Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41-6.
    • (1995) Am J Kidney Dis , vol.26 , pp. 41-46
    • Fishbane, S.1    Frei, G.L.2    Maesaka, J.3
  • 60
    • 0029952883 scopus 로고    scopus 로고
    • A randomized controlled study of iron supplementation in patients treated with erythropoietin
    • 1:CAS:528:DyaK28Xms1ylu70%3D 8914038
    • Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694-9.
    • (1996) Kidney Int , vol.50 , pp. 1694-1699
    • Macdougall, I.C.1    Tucker, B.2    Thompson, J.3
  • 61
    • 84940645637 scopus 로고    scopus 로고
    • A randomized, open-label trial of iron isomaltoside1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
    • Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;0:1-13. 10.1093/ndt/gfv096
    • (2015) Nephrol Dial Transplant , pp. 1-13
    • Bhandari, S.1    Kalra, P.A.2    Kothari, J.3
  • 62
    • 84973130364 scopus 로고    scopus 로고
    • Conference participants. Iron management in chronic kidney disease: Conclusions from a "kidney disease: Improving global outcomes" (KDIGO) controversies conference
    • 1:CAS:528:DC%2BC28XhtFOlsL3J 26759045
    • Macdougall IC, Bircher AJ, Eckardt KU, et al. Conference participants. Iron management in chronic kidney disease: conclusions from a "kidney disease: improving global outcomes" (KDIGO) controversies conference. Kidney Int. 2016;89(1):28-39.
    • (2016) Kidney Int , vol.89 , Issue.1 , pp. 28-39
    • Macdougall, I.C.1    Bircher, A.J.2    Eckardt, K.U.3
  • 63
    • 1342301446 scopus 로고    scopus 로고
    • Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients
    • 1:CAS:528:DC%2BD2cXitleksbk%3D 14871430
    • Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65(3):1091-8.
    • (2004) Kidney Int , vol.65 , Issue.3 , pp. 1091-1098
    • Canavese, C.1    Bergamo, D.2    Ciccone, G.3
  • 64
    • 84862558474 scopus 로고    scopus 로고
    • Evidence for tissue iron overload in long-term haemodialysis patients and the impact of withdrawing parenteral iron
    • 1:CAS:528:DC%2BC38Xht1Ght77J 22435497
    • Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term haemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87-93.
    • (2012) Eur J Haematol , vol.89 , Issue.1 , pp. 87-93
    • Ghoti, H.1    Rachmilewitz, E.A.2    Simon-Lopez, R.3
  • 65
    • 84864286737 scopus 로고    scopus 로고
    • Haemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study
    • 22998881
    • Rostoker G, Griuncelli M, Loridon C, et al. Haemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125(10):991-9.
    • (2012) Am J Med , vol.125 , Issue.10 , pp. 991-999
    • Rostoker, G.1    Griuncelli, M.2    Loridon, C.3
  • 66
    • 33947212276 scopus 로고    scopus 로고
    • DRIVE study group. Ferric gluconate is highly efficacious in anaemic haemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated Ferritin (DRIVE) study
    • 1:CAS:528:DC%2BD2sXjs1Grsb8%3D 17267740
    • Coyne DW, Kapoian T, Suki W, et al. DRIVE study group. Ferric gluconate is highly efficacious in anaemic haemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated Ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18:975-84.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 975-984
    • Coyne, D.W.1    Kapoian, T.2    Suki, W.3
  • 67
    • 27144498003 scopus 로고    scopus 로고
    • Double-blind comparison of full and partial anaemia correction in incident haemodialysis patients without symptomatic heart disease
    • 15901766
    • Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anaemia correction in incident haemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16(7):2180-9.
    • (2005) J Am Soc Nephrol , vol.16 , Issue.7 , pp. 2180-2189
    • Parfrey, P.S.1    Foley, R.N.2    Wittreich, B.H.3
  • 68
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving haemodialysis and epoetin
    • 1:CAS:528:DyaK1cXlvVyrtr8%3D 9718377
    • Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving haemodialysis and epoetin. N Engl J Med. 1998;339(9):584-90.
    • (1998) N Engl J Med , vol.339 , Issue.9 , pp. 584-590
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3
  • 69
    • 33750983605 scopus 로고    scopus 로고
    • Correction of anaemia with epoetin alfa in chronic kidney disease
    • 1:CAS:528:DC%2BD28Xht1Wqt7fN 17108343
    • Singh AK, Szczech L, Tang KL, et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-98.
    • (2006) N Engl J Med , vol.355 , Issue.20 , pp. 2085-2098
    • Singh, A.K.1    Szczech, L.2    Tang, K.L.3
  • 70
    • 33751002326 scopus 로고    scopus 로고
    • Normalization of haemoglobin level in patients with chronic kidney disease and anaemia
    • 17108342
    • Drüeke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anaemia. N Engl J Med. 2006;355(20):2071-84.
    • (2006) N Engl J Med , vol.355 , Issue.20 , pp. 2071-2084
    • Drüeke, T.B.1    Locatelli, F.2    Clyne, N.3
  • 71
    • 85037036242 scopus 로고    scopus 로고
    • (PROCRIT ®: Clinical Study Report PR00-06-014 (CHOIR) Synopsis, 12 September 2006 Accessed 15 June 2017
    • (PROCRIT ®: Clinical Study Report PR00-06-014 (CHOIR) Synopsis, 12 September 2006; available at: www.clinicaltrials.gov. Accessed 15 June 2017.
  • 72
    • 50849110807 scopus 로고    scopus 로고
    • Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved haemoglobin outcomes
    • 1:CAS:528:DC%2BD1cXhtVGgtbjN 18596733 2902279
    • Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved haemoglobin outcomes. Kidney Int. 2008;74(6):791-8.
    • (2008) Kidney Int , vol.74 , Issue.6 , pp. 791-798
    • Szczech, L.A.1    Barnhart, H.X.2    Inrig, J.K.3
  • 73
    • 74449085180 scopus 로고    scopus 로고
    • A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anaemia treatment
    • 1:CAS:528:DC%2BC3cXntVemtg%3D%3D 19890274
    • Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anaemia treatment. Kidney Int. 2010;77(3):239-46.
    • (2010) Kidney Int , vol.77 , Issue.3 , pp. 239-246
    • Szczech, L.A.1    Barnhart, H.X.2    Sapp, S.3
  • 74
    • 34548046760 scopus 로고    scopus 로고
    • KDOQI clinical practice guideline and clinical practice recommendations for anaemia in chronic kidney disease, 2007 update of haemoglobin target
    • KDOQI clinical practice guideline and clinical practice recommendations for anaemia in chronic kidney disease, 2007 update of haemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.
    • (2007) Am J Kidney Dis. , vol.50 , Issue.3 , pp. 471-530
  • 75
    • 70949108082 scopus 로고    scopus 로고
    • A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    • 19880844
    • Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-32.
    • (2009) N Engl J Med , vol.361 , Issue.21 , pp. 2019-2032
    • Pfeffer, M.A.1    Burdmann, E.A.2    Chen, C.Y.3
  • 76
    • 77649227625 scopus 로고    scopus 로고
    • Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: An observational study using UK renal registry data incorporating 30,040 patient-years of follow-up
    • 1:CAS:528:DC%2BC3cXislajt74%3D 19934090
    • Macdougall IC, Tomson CR, Steenkamp M, et al. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK renal registry data incorporating 30,040 patient-years of follow-up. Nephrol Dial Transplant. 2010;25(3):914-9.
    • (2010) Nephrol Dial Transplant , vol.25 , Issue.3 , pp. 914-919
    • Macdougall, I.C.1    Tomson, C.R.2    Steenkamp, M.3
  • 77
    • 77649193846 scopus 로고    scopus 로고
    • Comparative mortality risk of anaemia management practices in incident haemodialysis patients
    • 1:CAS:528:DC%2BC3cXivFyms78%3D 20197532
    • Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anaemia management practices in incident haemodialysis patients. JAMA. 2010;303(9):857-64.
    • (2010) JAMA , vol.303 , Issue.9 , pp. 857-864
    • Brookhart, M.A.1    Schneeweiss, S.2    Avorn, J.3
  • 78
    • 77956255701 scopus 로고    scopus 로고
    • Anaemia working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the trial to reduce cardiovascular events with Aranesp therapy (TREAT) study
    • 20591813
    • Locatelli F, Aljama P, Canaud B, et al. Anaemia working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25(9):2846-50.
    • (2010) Nephrol Dial Transplant , vol.25 , Issue.9 , pp. 2846-2850
    • Locatelli, F.1    Aljama, P.2    Canaud, B.3
  • 79
    • 85037036148 scopus 로고    scopus 로고
    • UK Renal Registry Accessed 15 June 2017
    • UK Renal Registry. UK Renal Registry Report: The fourteenth Annual Report. 2011. https://www.renalreg.org/wp-content/uploads/2014/09/Chap08-Renal11-web.pdf. Accessed 15 June 2017.
    • (2011) UK Renal Registry Report: The Fourteenth Annual Report
  • 80
    • 85037043986 scopus 로고    scopus 로고
    • Medicines and Healthcare products Regulatory Agency: Recombinant human erythropoietins: new advice for prescribing Accessed 15 June 2017
    • Medicines and Healthcare products Regulatory Agency: Recombinant human erythropoietins: new advice for prescribing. https://www.gov.uk/drug-safety-update/recombinant-human-erythropoietins-new-advice-for-prescribing. Accessed 15 June 2017.
  • 81
    • 0024790160 scopus 로고
    • Recombinant human erythropoietin in anaemic patients with end-stage renal disease. Results of a phase III multicentre clinical trial
    • 1:STN:280:DyaK3c%2FoslCquw%3D%3D 2688507
    • Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anaemic patients with end-stage renal disease. Results of a phase III multicentre clinical trial. Ann Intern Med. 1989;111(12):992-1000.
    • (1989) Ann Intern Med , vol.111 , Issue.12 , pp. 992-1000
    • Eschbach, J.W.1    Abdulhadi, M.H.2    Browne, J.K.3
  • 82
    • 0024345845 scopus 로고
    • Treatment of the anaemia of progressive renal failure with recombinant human erythropoietin
    • 1:STN:280:DyaL1MzhsVSlsg%3D%3D 2747747
    • Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anaemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989;321(3):158-63.
    • (1989) N Engl J Med , vol.321 , Issue.3 , pp. 158-163
    • Eschbach, J.W.1    Kelly, M.R.2    Haley, N.R.3
  • 83
    • 0034919301 scopus 로고    scopus 로고
    • Et al; European/ Australian NESP 980202 study group. Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency
    • 1:CAS:528:DC%2BD3MXmtVOntb0%3D 11473657
    • Locatelli F, Olivares J, Walker R. Et al; European/ Australian NESP 980202 study group. Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency. Kidney Int. 2001;60(2):741-7.
    • (2001) Kidney Int , vol.60 , Issue.2 , pp. 741-747
    • Locatelli, F.1    Olivares, J.2    Walker, R.3
  • 84
    • 0032572918 scopus 로고    scopus 로고
    • Subcutaneous compared with intravenous epoetin in patients receiving haemodialysis. Department of Veterans Affairs Cooperative Study Group on erythropoietin in Haemodialysis patients
    • 1:CAS:528:DyaK1cXlvVyrtr4%3D 9718376
    • Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving haemodialysis. Department of Veterans Affairs Cooperative Study Group on erythropoietin in Haemodialysis patients. N Engl J Med. 1998;339(9):578-83.
    • (1998) N Engl J Med , vol.339 , Issue.9 , pp. 578-583
    • Kaufman, J.S.1    Reda, D.J.2    Fye, C.L.3
  • 85
    • 0037317083 scopus 로고    scopus 로고
    • Treatment of anaemia in dialysis patients with unit dosing of darbepoetin α at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)
    • 1:CAS:528:DC%2BD3sXisVCls7s%3D 12543893
    • Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin α at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 2003;18:362-9.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 362-369
    • Locatelli, F.1    Canaud, B.2    Giacardy, F.3
  • 86
    • 0036436322 scopus 로고    scopus 로고
    • European/ Australian NESP 970200 study group. Randomized trial of darbepoetin alfa for treatment of renal anaemia at a reduced dose frequency compared with rHuEPO in dialysis patients
    • 1:CAS:528:DC%2BD38XpsFKlur0%3D 12427142
    • Vanrenterghem Y, Bárány P, Mann JF, et al. European/ Australian NESP 970200 study group. Randomized trial of darbepoetin alfa for treatment of renal anaemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62(6):2167-75.
    • (2002) Kidney Int , vol.62 , Issue.6 , pp. 2167-2175
    • Vanrenterghem, Y.1    Bárány, P.2    Mann, J.F.3
  • 87
    • 38349014009 scopus 로고    scopus 로고
    • RUBRA study investigators: C.E.R.A. Maintains stable control of haemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks
    • 1:CAS:528:DC%2BD1cXpt1ygtA%3D%3D 18004064
    • Spinowitz B, Coyne DW, Lok CE, et al. RUBRA study investigators: C.E.R.A. Maintains stable control of haemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008;28(2):280-9.
    • (2008) Am J Nephrol , vol.28 , Issue.2 , pp. 280-289
    • Spinowitz, B.1    Coyne, D.W.2    Lok, C.E.3
  • 88
    • 36249017329 scopus 로고    scopus 로고
    • Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by haemodialysis or peritoneal dialysis: A randomized trial
    • 1:CAS:528:DC%2BD1cXit1Sgtw%3D%3D 18037099
    • Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by haemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007;50(6):989-1000.
    • (2007) Am J Kidney Dis , vol.50 , Issue.6 , pp. 989-1000
    • Klinger, M.1    Arias, M.2    Vargemezis, V.3
  • 89
    • 23944434545 scopus 로고    scopus 로고
    • Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: A randomized clinical study
    • 15788469
    • Tolman C, Richardson D, Bartlett C, et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol. 2005;16:1463-70.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 1463-1470
    • Tolman, C.1    Richardson, D.2    Bartlett, C.3
  • 90
    • 11144356159 scopus 로고    scopus 로고
    • Darbepoetin α administered once monthly maintains haemoglobin levels in stable dialysis patients
    • 1:CAS:528:DC%2BD2cXitl2lu7g%3D 15031347
    • Jadoul M, Vanrenterghem Y, Foret M, et al. Darbepoetin α administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004;19:898-903.
    • (2004) Nephrol Dial Transplant , vol.19 , pp. 898-903
    • Jadoul, M.1    Vanrenterghem, Y.2    Foret, M.3
  • 91
    • 32644457068 scopus 로고    scopus 로고
    • Haemoglobin cycling in haemodialysis patients treated with recombinant human erythropoietin
    • 1:CAS:528:DC%2BD2MXhtVCjt7rE 16105069
    • Fishbane S, Berns JS. Haemoglobin cycling in haemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337-43.
    • (2005) Kidney Int , vol.68 , pp. 1337-1343
    • Fishbane, S.1    Berns, J.S.2
  • 92
    • 0036280663 scopus 로고    scopus 로고
    • Randomized, controlled trial of darbepoetin alfa for the treatment of anaemia in haemodialysis patients
    • 1:CAS:528:DC%2BD38Xlsl2itLY%3D 12087568
    • Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anaemia in haemodialysis patients. Am J Kidney Dis. 2002;40(1):110-8.5.
    • (2002) Am J Kidney Dis , vol.40 , Issue.1 , pp. 110-1105
    • Nissenson, A.R.1    Swan, S.K.2    Lindberg, J.S.3
  • 93
    • 85037042654 scopus 로고    scopus 로고
    • FDA presentation at Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting, 18 October 2010 Accessed 15 June 2017
    • FDA presentation at Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting, 18 October 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM231978.pdf. Accessed 15 June 2017.
  • 94
    • 77955722809 scopus 로고    scopus 로고
    • Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease
    • 20439566
    • Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23-33.
    • (2010) Ann Intern Med , vol.153 , Issue.1 , pp. 23-33
    • Palmer, S.C.1    Navaneethan, S.D.2    Craig, J.C.3
  • 95
    • 52049121838 scopus 로고    scopus 로고
    • Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for haemoglobin-survival paradox in haemodialysis
    • 1:CAS:528:DC%2BD1cXht1yisb3K 18760517 5500636
    • Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for haemoglobin-survival paradox in haemodialysis. Am J Kidney Dis. 2008;52:727-36.
    • (2008) Am J Kidney Dis , vol.52 , pp. 727-736
    • Streja, E.1    Kovesdy, C.P.2    Greenland, S.3
  • 96
    • 85037048152 scopus 로고    scopus 로고
    • MHRA Drug Safety Update Recombinant human erythropoietins: treating anaemia in cancer Accessed 15 June 2017
    • MHRA Drug Safety Update Recombinant human erythropoietins: treating anaemia in cancer. https://www.gov.uk/drug-safety-update/recombinant-human-erythropoietins-treating-anaemia-in-cance r. Accessed 15 June 2017.
  • 97
    • 78549286047 scopus 로고    scopus 로고
    • American Society of Haematology and the American Society of Clinical Oncology practice guideline update committee. American Society of Haematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer
    • 1:CAS:528:DC%2BC3cXhsFCiu7fM 20974674
    • Rizzo JD, Brouwers M, Hurley P, et al. American Society of Haematology and the American Society of Clinical Oncology practice guideline update committee. American Society of Haematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045-59.
    • (2010) Blood , vol.116 , Issue.20 , pp. 4045-4059
    • Rizzo, J.D.1    Brouwers, M.2    Hurley, P.3
  • 98
    • 85037039161 scopus 로고    scopus 로고
    • National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Erythropoiesis-stimulating agents Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer ha anaemia in people with cancer having chemotherapy. 2014. National Institute for Clinical Excellence Accessed 15 June 2017
    • National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Erythropoiesis-stimulating agents Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer ha anaemia in people with cancer having chemotherapy. 2014. National Institute for Clinical Excellence. https://www.nice.org.uk/guidance/ta323/resources/erythropoiesisstimulating-agents-epoetin-and-darbepoetin-for-treating-anaemia-in-people-with-cancer-having-chemotherapy-including-review-of-ta142-82602485230021. Accessed 15 June 2017.
  • 99
    • 0035228407 scopus 로고    scopus 로고
    • NKF-K/DOQI clinical practice guidelines for Anaemia of chronic kidney disease: update 2000
    • NKF-K/DOQI clinical practice guidelines for Anaemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37:S182-238.
    • (2001) Am J Kidney Dis. , vol.37 , pp. S182-238
  • 100
    • 58149333362 scopus 로고    scopus 로고
    • Combined high serum ferritin and low iron saturation in haemodialysis patients: The role of inflammation
    • 1:CAS:528:DC%2BD1cXhsVKmsLnL 18922994 2572292
    • Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in haemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691-701.
    • (2008) Clin J Am Soc Nephrol , vol.3 , pp. 1691-1701
    • Rambod, M.1    Kovesdy, C.P.2    Kalantar-Zadeh, K.3
  • 101
    • 79251526560 scopus 로고    scopus 로고
    • Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease
    • 1:CAS:528:DC%2BC3MXisVChsr4%3D 20876673 3022252
    • Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:77-83.
    • (2011) Clin J Am Soc Nephrol , vol.6 , pp. 77-83
    • Ferrari, P.1    Kulkarni, H.2    Dheda, S.3
  • 102
    • 84908459097 scopus 로고    scopus 로고
    • Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management
    • 1:CAS:528:DC%2BC2MXhtlehurw%3D 25420283 4222472
    • Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671-6.
    • (2014) Haematologica , vol.99 , Issue.11 , pp. 1671-1676
    • Rampton, D.1    Folkersen, J.2    Fishbane, S.3
  • 103
    • 0028271604 scopus 로고
    • Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis
    • 1:STN:280:DyaK2c7nsFemtg%3D%3D 7510461
    • Novey HS, Pahl M, Haydik I, et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72:224-8.
    • (1994) Ann Allergy , vol.72 , pp. 224-228
    • Novey, H.S.1    Pahl, M.2    Haydik, I.3
  • 104
    • 2442677622 scopus 로고    scopus 로고
    • Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease
    • 1:CAS:528:DC%2BD2cXltFKgtrs%3D 15149341
    • Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279-89.
    • (2004) Kidney Int , vol.65 , pp. 2279-2289
    • Agarwal, R.1    Vasavada, N.2    Sachs, N.G.3
  • 105
    • 0018898174 scopus 로고
    • Intravenous iron dextran in clinical medicine
    • 1:STN:280:DyaL3c7mtlWmsQ%3D%3D 6154155
    • Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243:1726-31.
    • (1980) JAMA , vol.243 , pp. 1726-1731
    • Hamstra, R.D.1    Block, M.H.2    Schocket, A.L.3
  • 106
    • 0029795844 scopus 로고    scopus 로고
    • The safety of intravenous iron dextran in haemodialysis patients
    • 1:CAS:528:DyaK28XmtlKgsbg%3D 8840942
    • Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in haemodialysis patients. Am J Kidney Dis. 1996;28:529-34.
    • (1996) Am J Kidney Dis , vol.28 , pp. 529-534
    • Fishbane, S.1    Ungureanu, V.D.2    Maesaka, J.K.3
  • 107
    • 0036233761 scopus 로고    scopus 로고
    • Ferrlecit publication committee. Sodium ferric gluconate complex in haemodialysis patients: Adverse reactions compared to placebo and iron dextran
    • 1:CAS:528:DC%2BD38XjvFWhs78%3D 11967034
    • Michael B, Coyne DW, Fishbane S, et al. Ferrlecit publication committee. Sodium ferric gluconate complex in haemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61(5):1830-9.
    • (2002) Kidney Int , vol.61 , Issue.5 , pp. 1830-1839
    • Michael, B.1    Coyne, D.W.2    Fishbane, S.3
  • 108
    • 85037039529 scopus 로고    scopus 로고
    • MHRA Drug Safety Update (2013) Intravenous iron and serious hypersensitivity reactions: strengthened recommendations Accessed 15 June 2017
    • MHRA Drug Safety Update (2013) Intravenous iron and serious hypersensitivity reactions: strengthened recommendations. https://www.gov.uk/drug-safety-update/intravenous-iron-and-serious-hypersensitivity-reactions-strengthened-recommendations. Accessed 15 June 2017.
  • 109
    • 0038119551 scopus 로고    scopus 로고
    • Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin
    • 1:CAS:528:DC%2BD3sXmsFyrsr4%3D 12846752
    • Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003;64:572-8.
    • (2003) Kidney Int , vol.64 , pp. 572-578
    • Weiss, G.1    Meusburger, E.2    Radacher, G.3
  • 110
    • 78449290415 scopus 로고    scopus 로고
    • The struggle for iron - A metal at the host-pathogen interface
    • 1:CAS:528:DC%2BC3cXhsFansLbJ 20964797
    • Nairz M, Schroll A, Sonnweber T, Weiss G, et al. The struggle for iron - a metal at the host-pathogen interface. Cell Microbiol. 2010;12:1691-702.
    • (2010) Cell Microbiol , vol.12 , pp. 1691-1702
    • Nairz, M.1    Schroll, A.2    Sonnweber, T.3    Weiss, G.4
  • 111
    • 64049100955 scopus 로고    scopus 로고
    • Iron in innate immunity: Starve the invaders
    • 1:CAS:528:DC%2BD1MXksVCntrc%3D 19231148 2668730
    • Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol. 2009;21:63-7.
    • (2009) Curr Opin Immunol , vol.21 , pp. 63-67
    • Ganz, T.1
  • 112
    • 58149345129 scopus 로고    scopus 로고
    • Nramp1-functionality increases iNOS expression via repression of IL-10 formation
    • 1:CAS:528:DC%2BD1cXhsVymsLjK 18991287
    • Fritsche G, Nairz M, Werner ER, et al. Nramp1-functionality increases iNOS expression via repression of IL-10 formation. Eur J Immunol. 2008;38:3060-7.
    • (2008) Eur J Immunol , vol.38 , pp. 3060-3067
    • Fritsche, G.1    Nairz, M.2    Werner, E.R.3
  • 113
    • 14744278436 scopus 로고    scopus 로고
    • Anemia of chronic disease
    • 1:CAS:528:DC%2BD2MXit1Wkt7Y%3D 15758012
    • Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-23.
    • (2005) N Engl J Med , vol.352 , pp. 1011-1023
    • Weiss, G.1    Goodnough, L.T.2
  • 114
    • 84897423286 scopus 로고    scopus 로고
    • Distinct immunologic effects of different intravenous iron preparations on monocytes
    • 1:CAS:528:DC%2BC2cXlsFOns7k%3D 24523357 3967833
    • Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant. 2014;29:809-22.
    • (2014) Nephrol Dial Transplant , vol.29 , pp. 809-822
    • Fell, L.H.1    Zawada, A.M.2    Rogacev, K.S.3
  • 115
    • 84892159757 scopus 로고    scopus 로고
    • Iron and infection in haemodialysis patients
    • 24329610
    • Ishida JH, Johansen KL. Iron and infection in haemodialysis patients. Semin Dial. 2014;27(1):26-36.
    • (2014) Semin Dial , vol.27 , Issue.1 , pp. 26-36
    • Ishida, J.H.1    Johansen, K.L.2
  • 116
    • 84879979126 scopus 로고    scopus 로고
    • Infection risk with bolus versus maintenance iron supplementation in haemodialysis patients
    • 1:CAS:528:DC%2BC3sXht1Wkt7zJ 23787911 3699831
    • Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in haemodialysis patients. J Am Soc Nephrol. 2013;24(7):1151-8.
    • (2013) J Am Soc Nephrol , vol.24 , Issue.7 , pp. 1151-1158
    • Brookhart, M.A.1    Freburger, J.K.2    Ellis, A.R.3
  • 117
    • 84926225569 scopus 로고    scopus 로고
    • Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients
    • 1:CAS:528:DC%2BC2cXntVSmu70%3D 24759150
    • Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86(4):845-54.
    • (2014) Kidney Int , vol.86 , Issue.4 , pp. 845-854
    • Kuragano, T.1    Matsumura, O.2    Matsuda, A.3
  • 118
    • 0036191165 scopus 로고    scopus 로고
    • Iron administration and clinical outcomes in haemodialysis patients
    • 1:CAS:528:DC%2BD38Xit1WrtL8%3D 11856779
    • Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in haemodialysis patients. J Am Soc Nephrol. 2002;13(3):734-44.
    • (2002) J Am Soc Nephrol , vol.13 , Issue.3 , pp. 734-744
    • Feldman, H.I.1    Santanna, J.2    Guo, W.3
  • 119
    • 2542429341 scopus 로고    scopus 로고
    • Administration of parenteral iron and mortality among haemodialysis patients
    • 1:CAS:528:DC%2BD2cXktVWiu7s%3D 15153574
    • Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among haemodialysis patients. J Am Soc Nephrol. 2004;15(6):1623-32.
    • (2004) J Am Soc Nephrol , vol.15 , Issue.6 , pp. 1623-1632
    • Feldman, H.I.1    Joffe, M.2    Robinson, B.3
  • 120
    • 33644824809 scopus 로고    scopus 로고
    • Time-dependent associations between iron and mortality in haemodialysis patients
    • 1:CAS:528:DC%2BD2MXhtFegtLbO 16033854
    • Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in haemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070-80.
    • (2005) J Am Soc Nephrol , vol.16 , Issue.10 , pp. 3070-3080
    • Kalantar-Zadeh, K.1    Regidor, D.L.2    McAllister, C.J.3
  • 121
    • 84891434596 scopus 로고    scopus 로고
    • Intravenous iron supplementation practices and short-term risk of cardiovascular events in haemodialysis patients
    • 1:CAS:528:DC%2BC3sXhsleqt7bP 24223866 3815308
    • Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in haemodialysis patients. PLoS One. 2013;8(11):e78930.
    • (2013) PLoS One , vol.8 , Issue.11 , pp. e78930
    • Kshirsagar, A.V.1    Freburger, J.K.2    Ellis, A.R.3
  • 122
    • 0031959987 scopus 로고    scopus 로고
    • EPIBACDIAL: A multicentre prospective study of risk factors for bacteraemia in chronic haemodialysis patients
    • 1:STN:280:DyaK1c3lsFGhtg%3D%3D 9596085
    • Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicentre prospective study of risk factors for bacteraemia in chronic haemodialysis patients. J Am Soc Nephrol. 1998;9:869-76.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 869-876
    • Hoen, B.1    Paul-Dauphin, A.2    Hestin, D.3
  • 123
    • 0035985424 scopus 로고    scopus 로고
    • Intravenous iron administration does not significantly increase the risk of bacteraemia in chronic haemodialysis patients
    • 1:STN:280:DC%2BD38zjs1Omsw%3D%3D 12078950
    • Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteraemia in chronic haemodialysis patients. Clin Nephrol. 2002;57(6):457-61.
    • (2002) Clin Nephrol , vol.57 , Issue.6 , pp. 457-461
    • Hoen, B.1    Paul-Dauphin, A.2    Kessler, M.3
  • 124
    • 0033809678 scopus 로고    scopus 로고
    • European best practice guidelines 14-16: Inadequate response to epoetin
    • 11052148
    • Horl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant. 2000;15(Suppl 4):43-50.
    • (2000) Nephrol Dial Transplant , vol.15 , pp. 43-50
    • Horl, W.H.1    Jacobs, C.2    Macdougall, I.C.3
  • 125
    • 0031958358 scopus 로고    scopus 로고
    • Recombinant human erythropoietin: 10 years of clinical experience
    • 1:CAS:528:DyaK1cXis1Wkt74%3D 9566483
    • Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant. 1998;13(Suppl 2):3-8.
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 3-8
    • Winearls, C.G.1
  • 126
    • 0033810113 scopus 로고    scopus 로고
    • European best practice guidelines 5: Target haemoglobin
    • 11052145
    • Jacobs C, Horl WH, Macdougall IC, et al. European best practice guidelines 5: target haemoglobin. Nephrol Dial Transplant. 2000;15(Suppl 4):15-9.
    • (2000) Nephrol Dial Transplant , vol.15 , pp. 15-19
    • Jacobs, C.1    Horl, W.H.2    Macdougall, I.C.3
  • 127
    • 0016809584 scopus 로고
    • Pure red cell aplasia: Studies on an IgG serum inhibitor neutralizing erythropoietin
    • 1:STN:280:DyaE28%2Fmt1aitg%3D%3D 1201224
    • Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol. 1975;30:411.
    • (1975) Br J Haematol , vol.30 , pp. 411
    • Peschle, C.1    Marmont, A.M.2    Marone, G.3
  • 128
    • 19044392727 scopus 로고    scopus 로고
    • The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes
    • 15882278
    • Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346.
    • (2005) Kidney Int , vol.67 , pp. 2346
    • Boven, K.1    Stryker, S.2    Knight, J.3
  • 129
    • 14044259130 scopus 로고    scopus 로고
    • Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk
    • 1:CAS:528:DC%2BD2cXnslOnur8%3D 15466278
    • Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol. 2004;15:2728.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 2728
    • Cournoyer, D.1    Toffelmire, E.B.2    Wells, G.A.3
  • 130
    • 0037075272 scopus 로고    scopus 로고
    • Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin
    • 1:CAS:528:DC%2BD38XhtFCktr8%3D 11844847
    • Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469.
    • (2002) N Engl J Med , vol.346 , pp. 469
    • Casadevall, N.1    Nataf, J.2    Viron, B.3
  • 131
    • 0942287103 scopus 로고    scopus 로고
    • Anti-erythropoietin antibodies and pure red cell aplasia
    • 14747386
    • Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol. 2004;15:398.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 398
    • Rossert, J.1    Casadevall, N.2    Eckardt, K.U.3
  • 132
    • 0038752054 scopus 로고    scopus 로고
    • Pure red-cell aplasia due to anti-erythropoietin antibodies
    • 12686654
    • Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant. 2003;18:865.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 865
    • Eckardt, K.U.1    Casadevall, N.2
  • 133
    • 0036707892 scopus 로고    scopus 로고
    • Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins
    • 12191983
    • Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381.
    • (2002) J Am Soc Nephrol , vol.13 , pp. 2381
    • Weber, G.1    Gross, J.2    Kromminga, A.3
  • 134
    • 38749144042 scopus 로고    scopus 로고
    • Pure red cell aplasia induced by erythropoiesis-stimulating agents
    • 1:CAS:528:DC%2BD1cXhs1eitbw%3D 18178785
    • Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2008;3:193.
    • (2008) Clin J Am Soc Nephrol , vol.3 , pp. 193
    • Pollock, C.1    Johnson, D.W.2    Hörl, W.H.3
  • 135
    • 9644276661 scopus 로고    scopus 로고
    • Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia
    • 15522059
    • Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389.
    • (2004) Eur J Haematol , vol.73 , pp. 389
    • Casadevall, N.1    Cournoyer, D.2    Marsh, J.3
  • 136
    • 19044363751 scopus 로고    scopus 로고
    • Antibody-mediated pure red cell aplasia (PRCA) treatment and re- treatment: Multiple options
    • 15827054
    • Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re- treatment: multiple options. Nephrol Dial Transplant. 2005;20(Suppl 4):iv23.
    • (2005) Nephrol Dial Transplant , vol.20 , pp. iv23
    • Rossert, J.1    Macdougall, I.2    Casadevall, N.3
  • 137
    • 27744500483 scopus 로고    scopus 로고
    • Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the research on adverse drug events and reports (RADAR) project
    • 1:CAS:528:DC%2BD2MXht1ehsb7O 16099877 1895064
    • Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the research on adverse drug events and reports (RADAR) project. Blood. 2005;106:3343.
    • (2005) Blood , vol.106 , pp. 3343
    • Bennett, C.L.1    Cournoyer, D.2    Carson, K.R.3
  • 138
    • 2542553395 scopus 로고    scopus 로고
    • Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study
    • 1:CAS:528:DC%2BD2cXksVanu7g%3D 15172775
    • Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363(9423):1768-71.
    • (2004) Lancet , vol.363 , Issue.9423 , pp. 1768-1771
    • Verhelst, D.1    Rossert, J.2    Casadevall, N.3
  • 139
    • 85037041901 scopus 로고    scopus 로고
    • Accessed 15 June 2017
    • http://rarerenal.org/rare-disease-groups/pure-red-cell-aplasia-rdg/. Accessed 15 June 2017.
  • 140
    • 4644350897 scopus 로고    scopus 로고
    • Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes
    • 1:CAS:528:DC%2BD2cXot1aks7Y%3D 15467057
    • Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292(13):1555-62.
    • (2004) JAMA , vol.292 , Issue.13 , pp. 1555-1562
    • Rao, S.V.1    Jollis, J.G.2    Harrington, R.A.3
  • 141
    • 49749092336 scopus 로고    scopus 로고
    • Anaemia of chronic disease: A harmful disorder or an adaptive, beneficial response?
    • 18695181 2492976
    • Zarychanski R, Houston DS. Anaemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008;179(4):333-7.
    • (2008) CMAJ , vol.179 , Issue.4 , pp. 333-337
    • Zarychanski, R.1    Houston, D.S.2
  • 142
    • 0038488183 scopus 로고    scopus 로고
    • Causes of sensitisation in patients awaiting renal transplantation in Ireland
    • 1:STN:280:DC%2BD3s3ms1yjtw%3D%3D 12793472
    • Soosay A, O'Neill D, Counihan A, et al. Causes of sensitisation in patients awaiting renal transplantation in Ireland. Ir Med J. 2003;96(4):109-12.
    • (2003) Ir Med J , vol.96 , Issue.4 , pp. 109-112
    • Soosay, A.1    O'Neill, D.2    Counihan, A.3
  • 143
    • 0031748666 scopus 로고    scopus 로고
    • Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities
    • 1:CAS:528:DyaK1cXltVSnt70%3D 9681725
    • House AA, Pham B, Pagé DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant. 1998;13(7):1763-9.
    • (1998) Nephrol Dial Transplant , vol.13 , Issue.7 , pp. 1763-1769
    • House, A.A.1    Pham, B.2    Pagé, D.E.3
  • 144
    • 0030002368 scopus 로고    scopus 로고
    • Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure
    • 1:STN:280:DC%2BD2cvns1OqsA%3D%3D 15387752
    • Popovsky MA, Ransil BJ. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematology. 1996;12(1):1-3.
    • (1996) Immunohematology , vol.12 , Issue.1 , pp. 1-3
    • Popovsky, M.A.1    Ransil, B.J.2
  • 146
    • 84992700609 scopus 로고    scopus 로고
    • National Institute for Clinical Excellence Accessed 15 June 2017
    • National Institute for Clinical Excellence. Blood transfusion https://www.nice.org.uk/guidance/ng24/resources/blood-transfusion-1837331897029. Accessed 15 June 2017.
    • Blood Transfusion
  • 147
    • 85037030658 scopus 로고    scopus 로고
    • SaBTO (2015) HEV SCT Clinician Letter draft v0.3i Accessed 15 June 2017
    • SaBTO (2015) HEV SCT Clinician Letter draft v0.3i. http://hospital.blood.co.uk/media/27890/sabto-hev-clinician-letter-sct-12-08-15.pdf. Accessed 15 June 2017.
  • 148
    • 0036589880 scopus 로고    scopus 로고
    • Late post-transplant anaemia in adult renal transplant recipients. An under-recognized problem?
    • 12123208
    • Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anaemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant. 2002;2(5):429-35.
    • (2002) Am J Transplant , vol.2 , Issue.5 , pp. 429-435
    • Yorgin, P.D.1    Scandling, J.D.2    Belson, A.3
  • 149
    • 0036894170 scopus 로고    scopus 로고
    • Unexpectedly high prevalence of post-transplant anaemia in paediatric and young adult renal transplant recipients
    • 1:CAS:528:DC%2BD38Xps1OktrY%3D 12460052
    • Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of post-transplant anaemia in paediatric and young adult renal transplant recipients. Am J Kidney Dis. 2002;40(6):1306-18.
    • (2002) Am J Kidney Dis , vol.40 , Issue.6 , pp. 1306-1318
    • Yorgin, P.D.1    Belson, A.2    Sanchez, J.3
  • 150
    • 10744233694 scopus 로고    scopus 로고
    • Prevalence and management of anaemia in renal transplant recipients: A European survey
    • 12814475
    • Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anaemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3(7):835-45.
    • (2003) Am J Transplant , vol.3 , Issue.7 , pp. 835-845
    • Vanrenterghem, Y.1    Ponticelli, C.2    Morales, J.M.3
  • 151
    • 0033638483 scopus 로고    scopus 로고
    • Haemolytic-uremic syndrome in association with both cyclosporine and tacrolimus
    • 1:CAS:528:DC%2BD3MXnt1WktA%3D%3D 11140243
    • Abraham KA, Little MA, Dorman AM, et al. Haemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int. 2000;13(6):443-7.
    • (2000) Transpl Int , vol.13 , Issue.6 , pp. 443-447
    • Abraham, K.A.1    Little, M.A.2    Dorman, A.M.3
  • 152
    • 0025909289 scopus 로고
    • Cyclosporine-induced thrombotic microangiopathy resulting in renal allograft loss and its successful reuse: A report of two cases
    • 1:STN:280:DyaK3M7ktlOhug%3D%3D 1996580
    • Epstein M, Landsberg D. Cyclosporine-induced thrombotic microangiopathy resulting in renal allograft loss and its successful reuse: a report of two cases. Am J Kidney Dis. 1991;17(3):346-8.
    • (1991) Am J Kidney Dis , vol.17 , Issue.3 , pp. 346-348
    • Epstein, M.1    Landsberg, D.2
  • 153
    • 0033820323 scopus 로고    scopus 로고
    • Cyclosporine and tacrolimus-associated thrombotic microangiopathy
    • 1:STN:280:DC%2BD3cvpsVeiug%3D%3D 11007689
    • Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000;36(4):844-50.
    • (2000) Am J Kidney Dis , vol.36 , Issue.4 , pp. 844-850
    • Pham, P.T.1    Peng, A.2    Wilkinson, A.H.3
  • 154
    • 0033608465 scopus 로고    scopus 로고
    • Report of two cases and review of the literature
    • 1:CAS:528:DyaK1MXhvVKrtL4%3D 10071024
    • Trimarchi HM, Truong LD, Brennan S, et al. Report of two cases and review of the literature. Transplantation. 1999;67(4):539-44.
    • (1999) Transplantation , vol.67 , Issue.4 , pp. 539-544
    • Trimarchi, H.M.1    Truong, L.D.2    Brennan, S.3
  • 155
    • 0032991739 scopus 로고    scopus 로고
    • Cyclosporine associated thrombotic microangiopathy in renal allografts
    • 1:CAS:528:DyaK1MXjvFajtL4%3D 10354295
    • Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55(6):2457-66.
    • (1999) Kidney Int , vol.55 , Issue.6 , pp. 2457-2466
    • Zarifian, A.1    Meleg-Smith, S.2    O'Donovan, R.3
  • 156
    • 85047696530 scopus 로고
    • Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy
    • 1:STN:280:DyaK2M%2FpvVegsw%3D%3D 7800227
    • Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transplant. 1994;9(8):1191-3.
    • (1994) Nephrol Dial Transplant , vol.9 , Issue.8 , pp. 1191-1193
    • Dussol, B.1    Brunet, P.2    Vacher-Coponat, H.3
  • 157
    • 0029760317 scopus 로고    scopus 로고
    • Haemolytic uraemic syndrome associated with OKT3
    • 1:STN:280:DyaK2s%2FivFOqsg%3D%3D 8875800
    • Morris-Stiff G, Evans M, Baboolal K, et al. Haemolytic uraemic syndrome associated with OKT3. Transpl Int. 1996;9(5):522-3.
    • (1996) Transpl Int , vol.9 , Issue.5 , pp. 522-523
    • Morris-Stiff, G.1    Evans, M.2    Baboolal, K.3
  • 158
    • 0035956745 scopus 로고    scopus 로고
    • A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
    • RAPAMUNE Global Study Group 1:CAS:528:DC%2BD3MXhtF2msrw%3D 11213073
    • MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271-80.
    • (2001) Transplantation , vol.71 , Issue.2 , pp. 271-280
    • MacDonald, A.S.1
  • 159
    • 10744227990 scopus 로고    scopus 로고
    • Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience
    • 1:CAS:528:DC%2BD3sXksFGqt70%3D 12742465
    • Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc. 2003;35(3 Suppl):25S-34S.
    • (2003) Transplant Proc , vol.35 , Issue.3 , pp. 25S-34S
    • Kahan, B.D.1    Knight, R.2    Schoenberg, L.3
  • 160
    • 10044267849 scopus 로고    scopus 로고
    • Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients
    • 1:CAS:528:DC%2BD2MXhs1OrtA%3D%3D 15575902
    • Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4(12):2001-6.
    • (2004) Am J Transplant , vol.4 , Issue.12 , pp. 2001-2006
    • Augustine, J.J.1    Knauss, T.C.2    Schulak, J.A.3
  • 161
    • 13444260047 scopus 로고    scopus 로고
    • De novo thrombotic microangiopathy following treatment with sirolimus: Report of two cases
    • 15632351
    • Crew RJ, Radhakrishnan J, Cohen DJ, et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant. 2005;20(1):203-9.
    • (2005) Nephrol Dial Transplant , vol.20 , Issue.1 , pp. 203-209
    • Crew, R.J.1    Radhakrishnan, J.2    Cohen, D.J.3
  • 162
    • 1942506491 scopus 로고    scopus 로고
    • Pharmacoepidemiology of anaemia in kidney transplant recipients
    • 15100376
    • Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anaemia in kidney transplant recipients. J Am Soc Nephrol. 2004;15(5):1347-52.
    • (2004) J Am Soc Nephrol , vol.15 , Issue.5 , pp. 1347-1352
    • Winkelmayer, W.C.1    Kewalramani, R.2    Rutstein, M.3
  • 163
    • 0034861950 scopus 로고    scopus 로고
    • Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: Relationship with erythropoietin requirements
    • 11532682
    • Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis. 2001;38(3):510-7.
    • (2001) Am J Kidney Dis , vol.38 , Issue.3 , pp. 510-517
    • Le Meur, Y.1    Lorgeot, V.2    Comte, L.3
  • 164
    • 0141569624 scopus 로고    scopus 로고
    • Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic haemodialysis patients
    • 1:CAS:528:DC%2BD3sXms12ntrc%3D 12897465
    • Naito M, Kawashima A, Akiba T, Takanashi M, et al. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic haemodialysis patients. Am J Nephrol. 2003;23(5):287-93.
    • (2003) Am J Nephrol , vol.23 , Issue.5 , pp. 287-293
    • Naito, M.1    Kawashima, A.2    Akiba, T.3    Takanashi, M.4
  • 165
    • 0033670955 scopus 로고    scopus 로고
    • Pure red cell aplasia due to parvovirus B19 infection in a renal transplant patient: A case report
    • 1:STN:280:DC%2BD3MznsFaitw%3D%3D 11120017
    • So BJ, Chae KM, Lee KK, et al. Pure red cell aplasia due to parvovirus B19 infection in a renal transplant patient: a case report. Transplant Proc. 2000;32(7):1954-6.
    • (2000) Transplant Proc , vol.32 , Issue.7 , pp. 1954-1956
    • So, B.J.1    Chae, K.M.2    Lee, K.K.3
  • 166
    • 16244399174 scopus 로고    scopus 로고
    • Pure red cell aplasia associated with parvovirus B19 infection in renal transplantation: The first case report in Mexico
    • 15785387
    • Vales-Albertos LJ, García-Cárdenas M, Chávez-Becerra S, et al. Pure red cell aplasia associated with parvovirus B19 infection in renal transplantation: the first case report in Mexico. Transplantation. 2005;79(6):739.
    • (2005) Transplantation , vol.79 , Issue.6 , pp. 739
    • Vales-Albertos, L.J.1    García-Cárdenas, M.2    Chávez-Becerra, S.3
  • 167
    • 17144461151 scopus 로고    scopus 로고
    • Haemolytic anaemia after renal transplantation: Analysis of case reports
    • 14529899
    • Debska-Slizień A, Chamienia A, Król E, et al. Haemolytic anaemia after renal transplantation: analysis of case reports. Transplant Proc. 2003;35(6):2233-7.
    • (2003) Transplant Proc , vol.35 , Issue.6 , pp. 2233-2237
    • Debska-Slizień, A.1    Chamienia, A.2    Król, E.3
  • 168
    • 0035408088 scopus 로고    scopus 로고
    • Haemolytic anaemia caused by graft-versus host reaction in ABO-non identical renal transplants from blood group O donors
    • 1:STN:280:DC%2BD38%2FovVSlsQ%3D%3D 11816517
    • Peces R, Díaz Corte C, Navascués RA. Haemolytic anaemia caused by graft-versus host reaction in ABO-non identical renal transplants from blood group O donors. Nefrologia. 2001;21(4):395-401.
    • (2001) Nefrologia , vol.21 , Issue.4 , pp. 395-401
    • Peces, R.1    Díaz Corte, C.2    Navascués, R.A.3
  • 169
    • 0034518543 scopus 로고    scopus 로고
    • Alloimmune haemolysis after renal transplantation
    • 1:STN:280:DC%2BD3M7htFGqsQ%3D%3D 11146315
    • Li FK, Chan TM, Lai KN. Alloimmune haemolysis after renal transplantation. Am J Nephrol. 2000;20(6):473-5.
    • (2000) Am J Nephrol , vol.20 , Issue.6 , pp. 473-475
    • Li, F.K.1    Chan, T.M.2    Lai, K.N.3
  • 170
    • 0028968038 scopus 로고
    • Serum erythropoietin and reticulocyte maturity index after renal transplantation: A prospective longitudinal study
    • 1:STN:280:DyaK2M3nt1OltQ%3D%3D 7753259
    • Moulin B, Ollier J, George F. Serum erythropoietin and reticulocyte maturity index after renal transplantation: a prospective longitudinal study. Nephron. 1995;69(3):259-66.
    • (1995) Nephron , vol.69 , Issue.3 , pp. 259-266
    • Moulin, B.1    Ollier, J.2    George, F.3
  • 171
    • 0027299247 scopus 로고
    • Influence of the pre-transplant hematocrit level on early graft function in primary cadaveric renal transplantation
    • 1:STN:280:DyaK3s3mvFamtg%3D%3D 8497877
    • Schmidt R, Kupin W, Dumler F, et al. Influence of the pre-transplant hematocrit level on early graft function in primary cadaveric renal transplantation. Transplantation. 1993;55(5):1034-40.
    • (1993) Transplantation , vol.55 , Issue.5 , pp. 1034-1040
    • Schmidt, R.1    Kupin, W.2    Dumler, F.3
  • 172
    • 0029823737 scopus 로고    scopus 로고
    • Effect of pre-transplant erythropoietin therapy on renal allograft outcome
    • 1:STN:280:DyaK2s%2Fjt1Khtw%3D%3D 8878400
    • Vasquez EM, Pollack R. Effect of pre-transplant erythropoietin therapy on renal allograft outcome. Transplantation. 1996;62(7):1026-8.
    • (1996) Transplantation , vol.62 , Issue.7 , pp. 1026-1028
    • Vasquez, E.M.1    Pollack, R.2
  • 173
    • 0024705414 scopus 로고
    • Renal transplantation: Results in haemodialysis patients previously treated with recombinant human erythropoietin
    • 1:STN:280:DyaK3c%2FovFWksg%3D%3D 2688720
    • Paganini EP, Braun WE, Latham D, et al. Renal transplantation: results in haemodialysis patients previously treated with recombinant human erythropoietin. ASAIO Trans. 1989;35(3):535-8.
    • (1989) ASAIO Trans , vol.35 , Issue.3 , pp. 535-538
    • Paganini, E.P.1    Braun, W.E.2    Latham, D.3
  • 174
    • 0025931993 scopus 로고
    • Interrelationship between erythropoietin and erythropoiesis: Insights from renal transplantation
    • 1:STN:280:DyaK38%2Fis1Sksw%3D%3D 1928080
    • Lee DB. Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation. Am J Kidney Dis. 1991;18(4 Suppl 1):54-6.
    • (1991) Am J Kidney Dis , vol.18 , Issue.4 , pp. 54-56
    • Lee, D.B.1
  • 175
    • 0029798059 scopus 로고    scopus 로고
    • Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: A randomized prospective study
    • 8918628
    • Van Loo A, Vanholder R, Bernaert P, et al. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transplant. 1996;11(9):1815-21.
    • (1996) Nephrol Dial Transplant , vol.11 , Issue.9 , pp. 1815-1821
    • Van Loo, A.1    Vanholder, R.2    Bernaert, P.3
  • 176
    • 14544293681 scopus 로고    scopus 로고
    • Efficacy of erythropoietin administration in the treatment of anaemia immediately after renal transplantation
    • 1:CAS:528:DC%2BD2MXhtV2kt7w%3D 15699772
    • Van Biesen W, Vanholder R, Veys N, et al. Efficacy of erythropoietin administration in the treatment of anaemia immediately after renal transplantation. Transplantation. 2005;79(3):367-8.
    • (2005) Transplantation , vol.79 , Issue.3 , pp. 367-368
    • Van Biesen, W.1    Vanholder, R.2    Veys, N.3
  • 177
    • 0026595702 scopus 로고
    • Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure
    • 1:STN:280:DyaK383js1yksg%3D%3D 1314975
    • Jindal KK, Hirsch DJ, Belitsky P, et al. Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure. Nephrol Dial Transplant. 1992;7(2):143-6.
    • (1992) Nephrol Dial Transplant , vol.7 , Issue.2 , pp. 143-146
    • Jindal, K.K.1    Hirsch, D.J.2    Belitsky, P.3
  • 178
    • 0028544678 scopus 로고
    • Safety and efficacy of recombinant human erythropoietin in correcting the anaemia of patients with chronic renal allograft dysfunction
    • 1:STN:280:DyaK2M7nvVKrtQ%3D%3D 7873732
    • Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anaemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol. 1994;5(5):1216-22.
    • (1994) J Am Soc Nephrol , vol.5 , Issue.5 , pp. 1216-1222
    • Muirhead, N.1    Cattran, D.C.2    Zaltzman, J.3
  • 179
    • 0036714898 scopus 로고    scopus 로고
    • Erythropoietin therapy may retard progression in chronic renal transplant dysfunction
    • 1:CAS:528:DC%2BD38Xms1Klurc%3D 12198221
    • Becker BN, Becker YT, Leverson GE, Heisey DM. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant. 2002;17(9):1667-73.
    • (2002) Nephrol Dial Transplant , vol.17 , Issue.9 , pp. 1667-1673
    • Becker, B.N.1    Becker, Y.T.2    Leverson, G.E.3    Heisey, D.M.4
  • 180
    • 84856827831 scopus 로고    scopus 로고
    • For the CAPRIT study investigators. Correction of post kidney transplant anemia reduces progression of allograft nephropathy
    • 1:CAS:528:DC%2BC38Xjslamu7g%3D 22193388 3269184
    • Choukroun G, Kamar N, Dussol B, et al. For the CAPRIT study investigators. Correction of post kidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23(2):360-8.
    • (2012) J Am Soc Nephrol , vol.23 , Issue.2 , pp. 360-368
    • Choukroun, G.1    Kamar, N.2    Dussol, B.3
  • 181
    • 0028120887 scopus 로고
    • Recombinant human erythropoietin in renal transplant recipients with renal anaemia
    • 1:STN:280:DyaK2c7osVSlsQ%3D%3D
    • Traindl O, Barnas U, Franz M, et al. Recombinant human erythropoietin in renal transplant recipients with renal anaemia. Clin Transpl. 1994;8(1):45-8.
    • (1994) Clin Transpl , vol.8 , Issue.1 , pp. 45-48
    • Traindl, O.1    Barnas, U.2    Franz, M.3
  • 182
    • 0024463780 scopus 로고
    • Effects of recombinant human erythropoietin on the anaemia of renal transplant recipients with chronic rejection
    • 1:STN:280:DyaL1MzovFShsQ%3D%3D 2675414
    • Yoshimura N, Oka T, Ohmori Y, Aikawa I. Effects of recombinant human erythropoietin on the anaemia of renal transplant recipients with chronic rejection. Transplantation. 1989;48(3):527-9.
    • (1989) Transplantation , vol.48 , Issue.3 , pp. 527-529
    • Yoshimura, N.1    Oka, T.2    Ohmori, Y.3    Aikawa, I.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.